Clinical trials
Newly Diagnosed Multiple Myeloma clinical trials
Below are recruiting newly diagnosed multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 96 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07782944Recruiting
CD38 PET scan for multiple myeloma
This study uses a special PET scan that looks for a protein called CD38 on myeloma cells to see if it can better find and track multiple myeloma compared to the standard PET scan. It might help doctors plan your treatment more precisely.
Guilin, GuangxiAges 18 years+ - NCT05623020RecruitingPhase 3
New treatment for newly diagnosed transplant-ineligible myeloma
This Phase 3 study compares a three-drug combination (elranatamab, daratumumab, and lenalidomide) versus a standard three-drug treatment (daratumumab, bortezomib, lenalidomide, plus dexamethasone). It aims to see which plan works better for people newly diagnosed with multiple myeloma who cannot get a stem cell transplant.
Jupiter, FloridaAges 18 years+ - NCT04566328RecruitingPhase 3
Newly diagnosed multiple myeloma test of combination therapy
This Phase 3 trial tests a combination treatment approach for adults with newly diagnosed multiple myeloma, focusing on response and deeper remission. It may help by improving how well the disease is controlled early and measuring results beyond standard tests.
Anchorage, AlaskaAges 18 years+ - NCT06376526RecruitingPhase 2
Immunotherapy treatment for newly diagnosed multiple myeloma
This trial tests an immunotherapy drug combination for people newly diagnosed with multiple myeloma who have had some response to initial treatment but still have signs of disease. The goal is to see if this approach can help eliminate remaining cancer cells and potentially improve outcomes.
Miami, FloridaAges 18 years+ - NCT07285239RecruitingPhase 3
Comparing two drug combinations for newly diagnosed multiple myeloma
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
La Crosse, WisconsinAges 18–79 - NCT07764978RecruitingPhase 3
New drug combo for multiple myeloma without stem cell transplant
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT07409454RecruitingPhase 2
Post-transplant treatment for multiple myeloma with a bispecific antibody
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
TianjinAges 18 years+ - NCT07296627Recruiting
Real-world immunotherapy for newly diagnosed multiple myeloma
This study looks at how well first-line immunotherapy works for people newly diagnosed with multiple myeloma in real-world clinical settings in China. The goal is to understand what treatments are used and how patients respond.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07087964Recruiting
PET scans to better understand multiple myeloma risk and disease
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
Antwerp, AntwerpenAges 18 years+ - NCT06682156Recruiting
Switching to carfilzomib for multiple myeloma patients who can't tolerate bortezomib
This trial is for people newly diagnosed with multiple myeloma who are having side effects from their first treatment with bortezomib. It tests switching to a different drug called carfilzomib to see if it works well with fewer side effects.
Suzhou, JiangsuAges 18 years+ - NCT07652138RecruitingPhase 1
RN1201 injection for newly diagnosed multiple myeloma
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
Suzhou, JiangsuAges 18–70 - NCT07053436RecruitingPhase 2
New treatment for high-risk myeloma before transplant
This study tests a new treatment combination for people with high-risk multiple myeloma who are newly diagnosed and healthy enough for a stem cell transplant. The goal is to see if the treatment can improve outcomes compared to standard therapy.
Atlanta, GeorgiaAges 18 years+ - NCT05665140RecruitingPhase 2/Phase 3
Newly diagnosed myeloma study using blood-marker risk groups
This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.
BerlinAges 18–70 - NCT05558319RecruitingPhase 3
New myeloma study comparing three treatment plans before transplant
This Phase 3 trial tests the best combination of medicines for newly diagnosed multiple myeloma patients who are headed to an autologous stem cell transplant (ASCT). It compares extended VRD plus versus Isa-VRD versus Isa-V-Iberdomide to see which approach works best and is tolerable.
Alcalá de Henares, MadridAges 18–65 - NCT07045909RecruitingPhase 2
CAR-T cell therapy for newly diagnosed multiple myeloma
This trial tests an investigational CAR-T cell therapy (anitocabtagene autoleucel) in people with newly diagnosed multiple myeloma. It aims to see if this treatment is safe and effective when given after a short course of standard chemotherapy.
BadalonaAges 18–80 - NCT06768489RecruitingPhase 1
Study of a new drug combination for multiple myeloma
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
Denver, ColoradoAges 18 years+ - NCT04558931RecruitingPhase 2
NK cell therapy to help control multiple myeloma after initial treatment
This Phase 2 trial tests using your own immune cells (NK cells) alone or with isatuximab as “maintenance” treatment to help multiple myeloma stay under control after initial therapy. It may help lengthen the time until the disease grows again by boosting your immune response and targeting myeloma cells.
StockholmAges 18 years+ - NCT05091372RecruitingPhase 2
Maintenance treatment after transplant for newly diagnosed myeloma
This trial tests whether using belantamab mafodotin plus lenalidomide as long-term maintenance after an autologous stem cell transplant can keep multiple myeloma under control, guided by minimal residual disease (MRD). MRD is a very small amount of disease that may remain after transplant, and the study helps see if treating those patients better improves outcomes.
Houston, TexasAges 18 years+ - NCT05145400RecruitingPhase 2
Drug treatment for frail or older newly diagnosed multiple myeloma
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
Chapel Hill, North CarolinaAges 18 years+ - NCT05243797RecruitingPhase 3
Teclistamab plus lenalidomide maintenance after transplant
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
Phoenix, ArizonaAges 18 years+ - NCT05259553Recruiting
Testing blood markers in newly diagnosed multiple myeloma
This study looks at “biomarkers,” or measurable signals in blood, in people with multiple myeloma who are being treated for the first time. It may help researchers understand the disease better and how it responds to treatment.
LyonAges 18 years+ - NCT05344833RecruitingPhase 2
Isatuximab and lenalidomide after transplant for myeloma
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
Chicago, IllinoisAges 18 years+ - NCT05422027RecruitingPhase 1/Phase 2
Selinexor with VRd for high-risk newly diagnosed myeloma
This early-phase study tests whether selinexor combined with VRd (bortezomib, lenalidomide, and dexamethasone) can improve outcomes for people with high-risk, newly diagnosed multiple myeloma. You may be a candidate if you have certain lab/genetic signs of “high-risk” disease and haven’t had prior myeloma treatment.
Guangzhou, GuangdongAges 18 years+ - NCT05552222RecruitingPhase 3
New treatment combo study for newly diagnosed multiple myeloma
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
Gilbert, ArizonaAges 18 years+
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Newly Diagnosed Multiple Myeloma trials by city
Studies with a site in or near these metro areas.
Newly Diagnosed Multiple Myeloma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for newly diagnosed multiple myeloma?
- Yes. Clin2 currently lists 96 recruiting newly diagnosed multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a newly diagnosed multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a newly diagnosed multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.